In the phase I study of patients with stage III CRC treated with virus-like replicator particle (VRP)-CEA, 12 CRC patients completed standard postoperative adjuvant chemotherapy and received VRP-CEA immunization 4 times every 3 weeks. This evidence concerns the gene CEACAM5 and colorectal carcinoma.